emjreviews.com4m
Sanofi and Regeneron’s allergy drug approved as first biologic for COPD
Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...
copdnewstoday31m
FDA approves Dupixent for adults with poorly controlled COPD
The FDA has approved Dupixent as an add-on maintenance treatment for adults with poorly controlled COPD and high counts of ...
STAT1h
Pharmalittle: We’re reading about CVS under investor pressure, a final warning to J&J and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, ...
Regeneron (REGN) Receives a Buy from Barclays
Barclays analyst Carter Gould maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,220.00.
Yicai Global6h
China Approves World's First Targeted COPD Drug
The National Medical Products Administration approved Dupixent as an add-on maintenance treatment for adults with ...
Pharmabiz10h
China NMPA approves Sanofi & Regeneron’s Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD
China NMPA approves Sanofi & Regeneron’s Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD: Paris Monday, September 30, 2024, 11:00 Hrs [IST] The Nat ...
Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent set to advance in top drug sales
AbbVie Humira, Pfizer/BioNTech COVID-19 shot may not make top 10 pharma drugs in 2024, with Novo Nordisk Ozempic and ...